Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial
暂无分享,去创建一个
E. Antman | J. Mega | R. Giugliano | M. Sabatine | E. Braunwald | S. Murphy | M. Mercuri | F. Nordio | Joseph R. Walker | C. Ruff | James Lee | A. Vandell | Naveen Deenadayalu | J. Walker
[1] D. Boudreau,et al. Genetic Risk Factors for Major Bleeding in Patients Treated With Warfarin in a Community Setting , 2014, Clinical pharmacology and therapeutics.
[2] Munir Pirmohamed,et al. A Randomized Trial of Genotype-Guided Dosing of Warfarin , 2014 .
[3] Alexander Parkhomenko,et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.
[4] Hugh Calkins,et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.
[5] Rita Barallon,et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. , 2013, The New England journal of medicine.
[6] Janet Woodcock,et al. Pharmacogenetics and coumarin dosing--recalibrating expectations. , 2013, The New England journal of medicine.
[7] R. Califf,et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. , 2013, The New England journal of medicine.
[8] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[9] Yusuke Nakamura,et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study , 2013, The Lancet.
[10] S. Yusuf,et al. Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding , 2013, Circulation.
[11] A. Parkhomenko,et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.
[12] Gerhard Hindricks,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[13] Jeroen J. Bax,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. , 2012, European heart journal.
[14] M. Pirmohamed,et al. Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis , 2012, PloS one.
[15] R. Tait,et al. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates , 2012, British journal of haematology.
[16] B. Horne,et al. A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II) , 2012, Circulation.
[17] Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .
[18] M. Whirl‐Carrillo,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing , 2011, Clinical pharmacology and therapeutics.
[19] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[20] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[21] D. Berlowitz,et al. Risk-Adjusted Percent Time in Therapeutic Range as a Quality Indicator for Outpatient Oral Anticoagulation: Results of the Veterans Affairs Study To Improve Anticoagulation (VARIA) , 2011, Circulation. Cardiovascular quality and outcomes.
[22] Gregory Y H Lip,et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.
[23] E. Antman,et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). , 2010, American heart journal.
[24] Leon Poller,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[25] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[26] W. Baker,et al. Meta-Analysis to Assess the Quality of Warfarin Control in Atrial Fibrillation Patients in the United States , 2009, Journal of managed care pharmacy : JMCP.
[27] R. Altman,et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.
[28] Shiew-Mei Huang,et al. A Regulatory Science Perspective on Warfarin Therapy: A Pharmacogenetic Opportunity , 2009, Journal of clinical pharmacology.
[29] M. Rieder,et al. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients , 2008, Thrombosis and Haemostasis.
[30] Dan M Roden,et al. Genetic determinants of response to warfarin during initial anticoagulation. , 2008, The New England journal of medicine.
[31] D. Pollock,et al. National surveillance of emergency department visits for outpatient adverse drug events in children and adolescents. , 2008, The Journal of pediatrics.
[32] D. Wysowski,et al. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. , 2007, Archives of internal medicine.
[33] D. Pollock,et al. National surveillance of emergency department visits for outpatient adverse drug events. , 2006, JAMA.
[34] A. Forster,et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. , 2006, Chest.
[35] Deborah A Nickerson,et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.
[36] David L Veenstra,et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.
[37] J. Goldstein,et al. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. , 2002, Pharmacogenetics.
[38] M. Rich,et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. , 2001, JAMA.
[39] Martha J. Radford,et al. Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .
[40] J. Douketis,et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial , 2000, The Lancet.
[41] M. Margaglione,et al. Genetic Modulation of Oral Anticoagulation with Warfarin , 2000, Thrombosis and Haemostasis.
[42] G. Aithal,et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.
[43] F R Rosendaal,et al. A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.